Gastrointestinal stromal tumors

Authors

  • Jorge Soriano-Lorenzo Facultad de Medicina “Manuel Fajardo”, Universidad de Ciencias Médicas de La Habana. La Habana, Cuba
  • Mayte Lima-Pérez Servicio de Oncología Clínica, Hospital Clínico-Quirúrgico “Hermanos Ameijeiras”. La Habana, Cuba
  • Jorge Soriano-García Servicio de Oncología Clínica, Hospital Clínico-Quirúrgico “Hermanos Ameijeiras”. La Habana, Cuba
  • Karla Zaldívar-Blanco Facultad de Medicina “Manuel Fajardo”, Universidad de Ciencias Médicas de La Habana. La Habana, Cuba
  • Vilma Fleites-Calvo Servicio de Oncología Clínica, Hospital Clínico-Quirúrgico “Hermanos Ameijeiras”. La Habana, Cuba

DOI:

https://doi.org/10.15381/anales.802.16418

Abstract

Gastrointestinal stromal tumors (GIST) are mesenchymal neoplasms that arise in the gastrointestinal tract, usually in the stomach or the small intestine. GISTs can arise at any age, but more than 80% are reported in individuals older than 50 years men and women are affected at a roughly similar frequency. The few patients are who younger frequently have GIST associated with a syndrome. The clinical manifestations are non-specifics. The computer-tomography is recommended for staging and follow-up. The KIT and DOG1 are the most sensitive and specific immunohistochemistry markers. The standard treatment of localized GIST is complete surgical excision of the lesion, with or without adjuvant imatinib in dependence with the relapse risk. Neoadjuvant imatinib is the standard treatment for locally advanced and metastatic disease. In locally advanced and metastatic disease the imatinib treatment should be continued indefinitely. Following confirmed progression, or intolerance, to imatinib the standard second-line treatment is sunitinib.

Downloads

Published

2019-06-30

Issue

Vol. 80 No. 2 (2019)

Section

Artículos de Revisión

License

Copyright (c) 2019 Anales de la Facultad de Medicina

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Those authors who have publications with this magazine accept the following terms:

  1. Authors will retain their copyrights and guarantee the journal the right of first publication of their work, which will be simultaneously subject to Creative Commons Attribution License that allows third parties to share the work as long as its author and its first publication this magazine are indicated.
  2. Authors may adopt other non-exclusive licensing agreements for the distribution of the version of the published work (eg, deposit it in an institutional electronic file or publish it in a monographic volume) provided that the initial publication in this magazine is indicated.
  3. Authors are allowed and recommended to disseminate their work over the Internet (eg: in institutional telematic archives or on their website) before and during the submission process, which It can produce interesting exchanges and increase quotes from the published work. (See El efecto del acceso abierto ).

How to Cite

1.
Soriano-Lorenzo J, Lima-Pérez M, Soriano-García J, Zaldívar-Blanco K, Fleites-Calvo V. Gastrointestinal stromal tumors. An Fac med [Internet]. 2019 Jun. 30 [cited 2024 Jul. 17];80(2):214-21. Available from: https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/16418